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Impact of Variable RNA-Sequencing 
Depth on Gene Expression 
Signatures and Target Compound 
Robustness: Case Study Examining 
Brain Tumor (Glioma) Disease 
Progression
INTRODUCTION
Gene expression profiling examines the alter-
ing state of the transcriptome at many levels. In 
cancer research, gene expression profiling has 
been essential in assessing biologic function, 
pathogenesis, and biomarker discovery.1,2 In the 
past, microarrays have been used to measure gene 
expression; however, methodological drawbacks 
include background hybridization, reliance on 
established probes, and limited dynamic range.3-5 
A superior method available for gene expression 
Purpose Gene expression profiling can uncover biologic mechanisms underlying disease 
and is important in drug development. RNA sequencing (RNA-seq) is routinely used 
to assess gene expression, but costs remain high. Sample multiplexing reduces RNA-
seq costs; however, multiplexed samples have lower cDNA sequencing depth, which can 
hinder accurate differential gene expression detection. The impact of sequencing depth 
alteration on RNA-seq–based downstream analyses such as gene expression connectivity 
mapping is not known, where this method is used to identify potential therapeutic com-
pounds for repurposing.
Methods In this study, published RNA-seq profiles from patients with brain tumor (glioma) 
were assembled into two disease progression gene signature contrasts for astrocytoma. 
Available treatments for glioma have limited effectiveness, rendering this a disease of 
poor clinical outcome. Gene signatures were subsampled to simulate sequencing alter-
ations and analyzed in connectivity mapping to investigate target compound robustness.
Results Data loss to gene signatures led to the loss, gain, and consistent identification 
of significant connections. The most accurate gene signature contrast with consistent 
patient gene expression profiles was more resilient to data loss and identified robust 
target compounds. Target compounds lost included candidate compounds of potential 
clinical utility in glioma (eg, suramin, dasatinib). Lost connections may have been linked 
to low-abundance genes in the gene signature that closely characterized the disease phe-
notype. Consistently identified connections may have been related to highly expressed 
abundant genes that were ever-present in gene signatures, despite data reductions. Po-
tential noise surrounding findings included false-positive connections that were gained 
as a result of gene signature modification with data loss.
Conclusion Findings highlight the necessity for gene signature accuracy for connectivity 
mapping, which should improve the clinical utility of future target compound discover-
ies.
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measurement is RNA sequencing (RNA-seq) of 
cDNA transcripts in a high-throughput manner. 
Sequencing reads are then aligned to a refer-
ence genome or transcriptome and mapped to 
an identified region. Transcript abundance is 
estimated, facilitating the comparison of gene 
expression profiles. RNA-seq has wider ana-
lytical capabilities, including single nucleotide 
variants, insertion-deletions, gene splice variants, 
post-transcriptional modifications, and gene 
fusion detection, but remains costly.6,7 Exper-
imental techniques developed to minimize 
sequencing costs include sample multiplexing. 
Multiplexing involves labeling each sample 
library with a barcode identifier, allowing multi-
ple libraries to be pooled and sequenced simul-
taneously, reducing costs.7-10 Smaller volumes of 
RNA are analyzed for multiplexed samples; thus, 
the downside to multiplexing is reduced sequenc-
ing depth for this library type.
Accurate assessment of transcripts depends 
on length, abundance, and mappability to the 
reference and sufficient sequencing depth, par-
ticularly for genes with low transcript abun-
dance.11,12 Sequencing depth alterations can 
affect the detection of differentially expressed 
genes (DEGs) and potentially the accuracy of 
RNA-seq–based downstream analysis. Few stud-
ies have assessed the impact of sequencing depth 
alterations on RNA-seq downstream applica-
tions.13 More studies are required, particularly 
to assess applications that rely on precise gene 
signatures, informative in classifying cancer sub-
types and improved prognostic and predictive 
outcomes.14,15 A gene signature is summarized 
by DEGs that collectively represent the most 
prominent features of a cancer subtype or dis-
ease progression phenotype. If a gene signature 
is compiled using gene expression profiles with 
low sequencing depth, then it may not be fully 
representative of that phenotype. This could be 
particularly problematic for connectivity map-
ping that examines a gene expression signature 
contrast with the aim of predicting potentially 
therapeutic US Food and Drug–approved target 
compounds for repurposing.16
There is urgent need for new targeted therapies 
for gliomas, which are the most common form 
of primary brain tumor. Gliomas can be clas-
sified from grade I to IV on the basis of histo-
logic and molecular information.17 Depending 
on the cell of origin, each neoplasm is classified 
as an astrocytoma, oligodendroglioma, or ependy-
moma. Diffuse astrocytoma (WHO grade II) can 
demonstrate progression to anaplastic astrocy-
toma (WHO grade III) and malignant glioblas-
toma (GBM; WHO grade IV). Patient survival 
beyond 5 years is 58% for grade II astrocytoma, 
23.6% for grade III anaplastic astrocytoma, and 
only 5% for grade IV GBM.18-20 Patients with 
GBM undergo concurrent chemoradiother-
apy with temozolomide according to the Stupp 
protocol and adjuvant chemotherapy.21 Patients 
with anaplastic glioma may undergo radiother-
apy with or without chemotherapy, depending 
on tumor molecular profile.22 Low-grade glio-
mas with poor prognosis may also be considered 
for adjuvant treatment.23 There has been mini-
mal improvement in overall survival (14.6 v 12.2 
months)24; thus, new treatments are urgently 
sought for glioma. Herein, reference gene sig-
natures were compiled from publically available 
sequenced tumors for astrocytoma disease pro-
gression.2 Subsampling was applied to simulate 
sequencing depth alterations of gene signatures, 
and the performance of connectivity mapping 
was assessed. Results reveal that information 
loss to gene signatures significantly affects target 
compound robustness.
METHODS
Published whole transcriptome sequencing data 
of brain tumor biopsy specimens from adults 
(accession: GSE48865; Bao et al2) was down-
loaded from the Sequence Read Archive.25 On 
average, samples had 50 million reads each. Reads 
were quality controlled using Trimmomatic soft-
ware26 and aligned using Bowtie2,27 allowing one 
mismatch against the human genome version 
hg38.28 Aligned reads were mapped to genes from 
the GRCh38.81 annotation29 using samExploreR 
software.30,31
To benchmark a diverse range in performance 
of the RNA-seq analysis, mapped reads were 
subsampled to simulate samples with a range of 
lower cDNA library sequencing depths using 
a bioinformatics pipeline32 (Appendix Fig A1; 
Data Supplement). RNA-seq reads for tran-
script-level abundance to gene level were sum-
marized and normalized using the relative log 
expression method and analyzed for differen-
tial expression using full (f = 1.0) and simulated 
samples with DESeq2.33 Gene expression sig-
nature contrasts representative of astrocytoma 
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disease progression were compiled for low 
to high (L-H) and high to high (H-H)–grade 
astrocytoma (Data Supplement). Gene signa-
ture contrasts were assessed for consistency in 
a heatmap using pheatmap R package (http://
CRAN.R-project.org/package=pheatmap). The 
impact of information loss to gene signatures for 
DEGs, gene ontology (GO) terms, and target com-
pound detection was assessed using differential 
expression, GO, and gene expression connectiv-
ity mapping analysis, respectively, with DESeq2, 
GOseq, and the QUB Accelerated Drug and 
Transcriptomic Connectivity (QUADrATiC) 
software33-35 (Data Supplement). The reproduc-
ibility of significant connections to the Library 
of Integrated Cellular Signatures identified 
for all cell lines and neuronal specific cell lines 
(Data Supplement) by QUADrATiC was inves-
tigated16,36-38 (Data Supplement). Results and 
associated false discovery rates (FDRs) were 
visualized using the R packages VennDiagram 
and ggplot2.39,40
RESULTS
Assessment of the L-H and H-H Gene 
Expression Signatures
L-H (Dataset_I) and H-H (Dataset_II) gene sig-
nature contrasts comprised 47 and 33 patients, 
respectively (Data Supplement). Some 6,648 
DEGs were identified for Dataset_I, which 
reduced to 2,550 after filtering (Fig 1A). Just 
608 DEGs were identified for Dataset_II, 
reducing to 327 after filtering (Fig 1B). Each 
gene signature contrast clustered into two sep-
arate branches, which mostly stratified patients 
on the basis of disease grade (Figs 1C and 1D). 
Dataset_I outperformed Dataset_II; all but one 
patient clustered according to disease grade. For 
each gene signature contrast, no outliers outside 
of the two disease grades were identified.
Impact of Information Loss to Gene 
Signatures for DEG and GO Detection
For Dataset_I, initial reductions in data analyzed 
(f = 0.8 to 1.0) did not greatly affect the number 
of DEGs detected (Fig 1A). However, the rate of 
loss of DEGs increased after f = 0.8. For Data-
set_II, data loss was immediate, and DEG detec-
tion reduced equally for every fraction analyzed, 
as indicated by the linear relationship (Fig 1B). 
Variation in the number of DEGs detected was 
lower for Dataset_I compared with Dataset_II, 
as evidenced by smaller confidence intervals. 
When data input was reduced, the FDR for the 
number of DEGs detected increased linearly 
and by approximately the same amount for both 
data sets (Appendix Fig A2). Dataset_I gene sig-
nature therefore demonstrated better resilience 
to data loss for DEG detection compared with 
Dataset_II.
For the full data set (f = 1.0), > 200 GO terms 
described the functions of the DEGs identified 
for Dataset_I (Appendix Fig A3A). Thus, het-
erogeneous biologic functions are involved in 
low- to high-grade astrocytoma disease transi-
tion. For Dataset_I, only small decreases in GO 
terms were detected using data fractions between 
f = 1.0 and 0.1 (Appendix Fig A3A). Thus, GO term 
detection was more stable compared with DEGs 
when Dataset_I gene signature had data loss. 
The impact of data loss on FDR for GO term 
detection was on the same scale as that observed 
for DEG detection for Dataset_I (Fig A3B). 
Comparatively fewer GO terms, just three, 
described the DEGs in Dataset_II for the full 
data set. Given this low number, which reduced 
to zero on f = 0.5, GO results for subsampled 
Dataset_II are not depicted.
Impact of Information Loss to Gene 
Signatures Used in Gene Expression 
Connectivity Mapping
For the full data set, a greater number of sig-
nificant reverse (rev) and progress (prog) con-
nections were identified for Dataset_I compared 
with Dataset_II (Fig 2A). For Dataset_I, data 
loss did not greatly affect the number of signif-
icant rev and prog connections detected. With 
increasing data loss, Dataset_I significant con-
nections remained relatively stable (f = 1.0 to 0.7) 
and then slightly increased. For Dataset_II, rev 
significant connections decreased steadily with 
data loss, whereas prog connections were slightly 
more stable. Dataset_I displayed less variability 
in the number of significant connections iden-
tified, compared with Dataset_II, as evidenced 
by smaller confidence intervals. For both Data-
set_I and Dataset_II, FDR for the number of 
significant connections increased steadily with 
decreasing data used (Fig 2B). However, FDR 
was three-fold greater for Dataset_II and quickly 
increased to approximately 10% and 20% for 
rev and prog connections, respectively, when 
just 1% of reads were removed (f = 0.99). For 
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target compound identification, Dataset_I was 
therefore more resilient to alterations in cDNA 
sequencing depth compared with Dataset_II.
The impact of data loss to gene signatures and 
the reproducibility of connectivity mapping is 
presented in Figures 3-5. When full data sets 
were used for the gene signature (f = 1.0), tar-
get compound identification was consistent, and 
mostly the same compounds were identified 
between iterations (Figs 3, 4A, and 4C; frequency = 
1.0). With data loss to the gene signature (f = 
0.01, 0.5), fewer compounds were consistently 
identified, and a higher number of target com-
pounds were detected at low frequencies of 
iterations. For example, 3,135 rev connections 
were identified for Dataset_I using f = 1.0; this 
increased to approximately 5,000 when subsam-
pled to f = 0.01, but approximately 60% of com-
pounds were infrequently detected (Figs 3B and 
3C). Proportion of significant connections that 
are consistently identified decreases with data 
loss, but the impact was less for Dataset_I. For 
Dataset_I, when 50% of reads were removed, 
approximately 62.5% rev (approximately 2,500 
of 4,000) and approximately 50% prog signifi-
cant connections (approximately 1,500 of 3,000) 
were identified with every iteration (Fig 3). For 
Dataset_II, when 50% of reads were removed, 
just approximately 13% rev (approximately 400 
of 3,000) and 9% prog significant connections 
(approximately 180 of 2,000) were identified 
with every iteration (Fig 4). No robust calls were 
identified for Dataset_II at f = 0.01, and little 
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Fig 1. Effect of decreased cDNA library sequencing depth on the number of differentially expressed genes (DEGs) detected from (A) Dataset_I, 
and (B) Dataset_II gene signatures (Data Supplement). Visualization of the global stratification ability of (C) Dataset_I, low to high (L-H), and (D) 
Dataset_II, high to high (H-H) gene signatures. Dataset_I is composed of astrocytomas (ASTRO) and anaplastic astrocytomas (aASTRO). Dataset_
II is composed of aASTRO and secondary glioblastomas (sGBM). Heatmap was generated using unsupervised hierarchical clustering with the full 
RNA-seq data (f = 1) and depicts the gene expressional patterns of the top 100 differentially expressed genes identified between the gene signature 
contrast groups. The WHO disease grades of samples as determined by Bao et al2 are overlaid.
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improvement was observed when half the reads 
were included (f = 0.5; Fig 4). Gene signatures 
differed in the proportion of significant con-
nections that were consistently identified when 
cDNA sequencing depth was reduced. When 
affected by data loss, connectivity mapping 
results were more robust for Dataset_I com-
pared with the Dataset_II gene signature.
Reducing data to the gene signature led to the 
loss, gain, and consistent identification of signif-
icant connections to target compounds (Fig 5). 
Compounds consistently identified between data 
fractions can be seen within the Venn diagram 
intersections. For Dataset_I, a large proportion 
of the significant connections across all cell lines 
(69%; 2,195 of 3,135) and neuronal-specific cell 
lines (70%; 144 of 205) were detected with all 
data fractions. Similarly for Dataset_II, a pro-
portion of the significant connections across 
all cell lines (7%; 100 of 1,339) and neuronal- 
specific cell lines (5%; nine of 172) were detected 
with all data fractions. The gain in significant 
connections can be seen in the relative comple-
ment sections of the smaller data fractions in 
the Venn diagrams. For example, 350 and 105 
compounds were detected across all cell lines 
for Dataset_I, f = 0.01, that were not identified 
by the full data set (Fig 5A). These connections 
were false positives, because they had not been 
detected with the full gene signature. Last, we 
examined the loss of significant connections to 
target compounds for Dataset_I and II. When 
50% of the reads were removed, nine and 27 
target compounds identified for neuronal- 
specific cell lines were lost, respectively, for 
Dataset_I and II (Figs 5C and 5D; Table 1). Thus, 
for Dataset_II, more target compounds iden-
tified by the full gene signature were lost, and 
some of these included compounds of potential 
clinical utility for glioma, such as suramin and 
dasatinib (Table 1). A comparison of the rate of 
impact of data loss on GO terms and significant 
connections detection for Dataset_I can be seen 
by comparing Figures A3 and 2A.
DISCUSSION
Understanding molecular pathways and regula-
tory networks driving cancer is essential for the 
development of new therapies. Gene expression 
profiling using RNA-seq has led to the develop-
ment of clinically relevant gene signatures that 
are informative for cancer subtypes.14,15 RNA-
seq experimental approaches such as sample 
multiplexing reduce cDNA sequencing depth 
and potentially affect gene signature accuracy. 
This information loss may mask the true bio-
logic variability of a gene signature. Herein, 
sequence depth alterations in gene signatures 
were simulated and the impacts of data loss for 
gene expression connectivity mapping investi-
gated. Two gene signature contrasts representing 
astrocytoma disease progression were analyzed. 
Assessment of their global stratification ability 
revealed that the WHO grade II to III contrast 
(L-H; Dataset_I) outperformed the WHO grade 
III to IV contrast (H-H; Dataset_II), whereby 
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Fig 2. (A) Effect of 
decreased cDNA library 
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number of significant 
connections detected by 
connectivity mapping for 
Dataset_I and II gene sig-
natures. (B) False discovery 
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of significant connections 
detected in the connectiv-
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Fig 3. Frequency of progress (prog) and reverse (rev) significant connections to target compounds identified for Dataset_I and II gene signa-
tures. Results for three different subsampled data fractions (f = 0.01, 0.5, 1) each with 25 iterations are presented.
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Fig 4. Frequency of progress (prog) and reverse (rev) significant connections to target compounds identified for Dataset_II gene signatures. 
Results for three different subsampled data fractions (f = 0.01, 0.5, 1) each with 25 iterations are presented.
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more patient gene expression profiles matched 
their WHO grade classifications. Results sup-
port the subjective nature of tumor classifica-
tion, which has interobserver variability.41 Gene 
signatures provided a framework to assess con-
nectivity mapping output for a well-performing 
accurate versus a poorer-performing less accu-
rate contrast.
Characterization of the disease progression gene 
signatures revealed they differed in biologic com-
plexity. L-H gene signature had ten-fold more 
DEGs (approximately 2,550) compared with the 
H-H gene signature (327). Results demonstrated 
the possibility that more genes are involved in 
low- to high-grade astrocytoma disease transi-
tion. After data reduction, DEG loss was not 
immediate for the L-H gene signature, but with 
lowering fractions DEG loss increased. For the 
H-H gene signature, there was immediate and 
steady DEG loss with reduced data input. FDR 
for DEG detection increased linearly for both 
gene signatures; however, the range of FDR val-
ues was lower for the L-H gene signature. Thus, 
the L-H gene signature was more resilient to 
data loss for DEG detection and had greater test 
sensitivity compared with the H-H gene signa-
ture. Gene signatures also differed in their resil-
ience to data loss for the detection of significant 
connections to target compounds. Overall, the 
number of significant connections detected for 
the L-H gene signature was greater, most likely 
explained by the heterogeneous biologic mech-
anisms involved in low- to high-grade astrocy-
toma transition. With data loss, both rev and 
prog significant connections remained relatively 
stable for the L-H gene signature. Data loss led 
to a steady decrease in rev significant connec-
tions for the H-H gene signature; however, prog 
connections were initially more stable. For both 
gene signatures, the FDR of significant con-
nections increased with data loss. Overall FDR 
values and CIs were smaller for the L-H gene 
signature. For comparative purposes, consider 
an FDR of 0.1 as an acceptable threshold, where 
one in every 10 significant connections is a false 
positive. With data loss, this FDR threshold was 
reached by the L-H and H-H gene signatures, 
respectively, when 70% and just 1% of reads 
were removed. Thus, the L-H gene signature 
was more resilient to data loss for the detection 
of significant connections to target compounds 
using connectivity mapping.
Subsampling of gene signatures for connectiv-
ity mapping revealed that the suite of significant 
connections to target compounds became mod-
ified with data loss. Notably, some connections 
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Fig 5. Effect of 
decreased cDNA library 
sequencing depth on the 
number of significant 
connections to target 
compounds identified that 
could potentially reverse 
the disease phenotype. 
Significant connections to 
target compounds identified 
across all cell lines using (A) 
Dataset_I and (B) Data-
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to target compounds of potential clinical util-
ity were lost when the reads were reduced to 
50%. Compounds lost by the H-H gene sig-
nature (WHO grade III to IV) included sura-
min, lopinavir, dasatinib, and vincristine, which 
have already been considered as glioma treat-
ments. Suramin, an anticancer agent, inhibits 
the binding of growth factors understood to 
play a role in glioma progression, angiogene-
sis, and radioresistance and has been used to 
treat newly diagnosed GBMs.42,43 Lopinavir, a 
protease inhibitor, has reached phase II clinical 
trials for the treatment of high-grade glioma.44 
Dasatinib, a kinase inhibitor that acts on mem-
bers of the Src family of kinases, is well studied 
in glioma and has shown preclinical promise.45 
Vincristine, a spindle poison, is used in combi-
nation with procarbazine and lomustine to treat 
high-grade glioma and has also been successful 
in a phase III trial for the treatment of low-grade 
gliomas.22,46,47 Reductions in transcript abun-
dance probably led to the loss of low-abundance 
genes from the full gene signature and altered 
the DEGs detected, leading to the loss of these 
connectivity mapping connections. Perhaps low- 
abundance genes that closely characterize the 
disease phenotype may offer the greatest poten-
tial for target compound discovery. If this is the 
case, then the subsampling approach described 
herein could potentially identify these import-
ant links to target compounds. Fewer significant 
connections identified by the full data sets were 
lost by the L-H gene signature compared with 
the H-H gene signature, suggesting it was more 
resilient to data loss. It was interesting to note 
that reduction in cDNA sequencing depth of 
gene signatures also led to the gain of signifi-
cant connections to target compounds. Indeed, 
more significant connections were identified 
when fewer data were used for both gene sig-
natures; however, few of these connections were 
consistently identified between iterations. A 
greater proportion of significant connections 
were consistently identified with all iterations 
for the L-H gene signature compared with the 
H-H gene signature. For connections that were 
consistently identified, these may have related to 
the most highly expressed and abundant DEGs 
in the gene signature contrast. Similarly, in 
another subsampling RNA-seq study of healthy 
organisms from multiple taxa, highly expressed 
genes regulating metabolism and pathogenesis 
of disease were consistently identified even when 
downsampling RNA-seq reads to only 1 million 
reads,13 thereby corroborating our findings from 
diseased tumors.
Results highlight the need for determining the 
optimal cDNA sequencing depth for accurately 
identifying DEGs when compiling gene signa-
tures. In the future, RNA standard and spike-in 
controls may be useful to inform RNA-seq best 
practices.48 The accuracy of a gene signature was 
particularly important when carrying out addi-
tional downstream analyses, such as connectivity 
mapping. Information loss to gene signatures 
led to erroneous and false target compound dis-
coveries. Gene signatures with consistent sample 
classification and gene expression profiles were 
more resilient to data loss and provided robust 
target compound discoveries. Given the insta-
bility of gene expression, perhaps using ontol-
ogy types or ontotypes49 to characterize contrast 
phenotypes may be a more reliable approach 
compared with gene lists in connectivity map-
ping. Herein, we demonstrate the utility of 
QUADrATiC software at identifying US Food 
and Drug Administration–approved compounds 
that can be repurposed for glioma. Stringent 
filtering of connectivity mapping results is 
required to identify reliable significant connec-
tions. Subsampling revealed that the connec-
tions that were sensitive to data loss were linked 
to target compounds of potential clinical utility 
in glioma. These connections may have the best 
clinical promise for drug repurposing. Other 
target compounds sensitive to data loss are being 
tested for their biologic efficacy against glioma 
stem cells using clonogenic cell survival assays 
and Western blot analyses in ongoing studies by 
this research group. For the wider identification 
of potential therapeutic compounds for repur-
posing in glioma, gene signatures for oligoden-
droglioma and ependymoma disease progression 
could be analyzed using connectivity mapping in 
the future.
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dataset_type
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For t in types
For i in depths
For N in resample_N
For t in types
For f in f_lists
For N in resample_N
Read compounds
Subset compounds
Compounds
Compute frequencies
Add compound list
Plot histogram
Input:
Fig A1. Schematic 
depicting the bioinformatics 
pipeline implemented for 
the subsampling iterative 
analysis of connectivity 
mapping for target com-
pound identification. Sub-
sampling using 17 different 
data fractions (f = 0.01 to 
1.0) and 25 iterations per 
data fraction providing 
425 data sets with variable 
sequencing depth per gene 
signature. Count vectors 
were analyzed to detect dif-
ferentially expressed genes 
(DEGs) and saved as gene 
lists. Gene lists were sub-
sequently analyzed in con-
nectivity mapping for target 
compound identification. 
RNA-seq analysis measured 
DEG, gene ontology (GO) 
terms, and target compound 
identification for the low- to 
high- (Dataset_I) and the 
high- to high-grade (Data-
set_II) astrocytoma gene 
signatures.
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Fig A2. Effect of 
decreased cDNA library se-
quencing depth on the false 
discovery rate (FDR) for 
the number of differentially 
expressed genes (DEGs) 
detected for Dataset _I and 
Dataset_II gene signatures.
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Fig A3. Effect of 
decreased cDNA library 
sequencing depth on the 
number of gene ontology 
(GO) terms identified for 
(A) Dataset_I and (B) the 
false discovery rate (FDR) 
for the number of GO terms 
identified. GO analysis for 
Dataset_II identified just 
three pathways; therefore, 
results are not shown.
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